NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ:PLSE) concerning possible violations of federal securities laws.
On September 11, 2017, Pulse disclosed in a regulatory filing “that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System.” Pulse further disclosed that the “voluntary withdrawal on September 8, 2017, was the result of the FDA’s appropriate request for additional data that could not be provided within the Agency’s 90-day review period that would have otherwise ended on September 10, 2017.” On this news, shares of Pulse fell sharply during intraday trading on September 11, 2017. To obtain additional information, go to:
http://www.zlkdocs.com/PLSE-Info-Request-Form-6096
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170911006194/en/
